Powered by

-Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Jan 04, 2019 - ENP Newswire
Partnership Announcement

NASHVILLE - Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors (GPCRs) known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia.

'By joining forces with Vanderbilt University, one of the world's leading groups integrating basic...